Insulet Corp Dossier
|
SectorHealth Care IndustryMedical Devices Beta (adjusted)1.06 Intrinsic Value $354.86median of 6 methods · middle span $250-$451based on filings through 30 Jun 2026 Market Price $130.79Price as of 1 Oct 2026 Significantly undervaluedIntrinsic value is 171% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+171%) Data confidence Sign in to view data confidence Market Cap $9.1B Enterprise Value $9.5B Shares Outstanding 71M diluted Moat Rating Wide Next Earnings Date4 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Insulet retains strong operating momentum, led by international Omnipod adoption, product innovation and continued automated-insulin-delivery market expansion. The risk-reward is balanced by reduced U.S. Omnipod guidance and two 2026 voluntary medical-device corrections. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$144.00 Mean target$171.91 High · most bullish analyst$275.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $144.0018% U.S. Omnipod growth falls below the reduced guidance range, while additional quality events, replacement costs or adverse-event reports weaken adoption and execution. International growth fails to offset domestic deceleration. Base CaseCentral scenario $171.9158% Matches the consensus meanRevenue and Omnipod growth remain within the updated 2026 guidance ranges, with international strength and product enhancements compensating for moderated U.S. growth. Medical-device-correction costs and operational effects remain contained. Bull CaseUpside scenario $275.0024% Insulet delivers near or above the upper end of its 2026 growth ranges as international expansion, the enhanced Omnipod 5 algorithm, broader sensor compatibility and additional country launches offset slower U.S. growth. Successful execution of the EVOLVE program would further strengthen the long-term type 2 diabetes opportunity. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |